Becton, Dickinson and Company
Parts of this article (those related to documentation) need to be updated.(January 2022)
|Industry||Medical equipment, Consulting|
|Founded||East Rutherford, New Jersey (1897 )|
|Founder||Maxwell Becton and Fairleigh S. Dickinson|
|Revenue||US$20.248 Billion (Fiscal Year Ended September 30, 2021)|
|US$2.799 Billion (Fiscal Year Ended September 30, 2021)|
|US$2.002 Billion (Fiscal Year Ended September 30, 2021)|
|Total assets||US$53.866 Billion (Fiscal Year Ended September 30, 2021)|
|Total equity||US$23.677 Billion (Fiscal Year Ended September 30, 2021)|
Number of employees
|Divisions||BD Medical; BD Life Sciences; BD Interventional|
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
In April 2017, C. R. Bard announced that it would be acquired by Becton, Dickinson and Company (BD). The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick injury. The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.
For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson's shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.
in mil. USD$
in mil. USD$
in mil. USD$
|Price per Share
Currently there are three business segments.
In certain places, BD Medical also offers consulting and analytics related services. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.
BD Life Sciences
Business units include Biosciences and Integrated Diagnostic Solutions.
Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.
As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek's 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.
2016 Health and safety issues
In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
2007 Discardit II incident in Poland
In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
2010 Q-Syte Luer and IV Catheter partial recall
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
2021 IV Giving Sets
In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
- Becton, Dickinson and Company headquarters
- List of biotech and pharmaceutical companies in the New York metropolitan area
- "Tom Polen". bd.com. Retrieved 2 December 2021.
- "Christopher R. Reidy". bd.com. Retrieved 2 December 2021.
- "Christopher DelOrefice". bd.com. Retrieved 2 December 2021.
- "Becton, Dickson and Company 2021 Annual Report". investors.bd.com. 30 September 2021. Retrieved 22 February 2022.
- "Fortune 500 List -2021". Fortune Magazine. Fortune Media IP Limited. Retrieved 6 February 2022.
- "Becton Dickinson to buy CareFusion for $12 billion in cash, stock". Reuters. 2014-10-06. Retrieved 2021-12-10.
- Walsh, Marsh (3 July 2004). "Syringe Manufacturer Settles Claim of Market Manipulation". The New York Times. Retrieved 26 February 2019.
- Perriello, Brad (5 December 2016). "UPDATE: Retractable Technologies plummets after appeals court tosses $352m win over Becton Dickinson". Mass Device. Retrieved 27 February 2019.
- "Becton Dickinson Revenue 2006–2018 | BDX". www.macrotrends.net. Retrieved 2018-11-06.
- Leslie DeLong; Nancy Burkhart (25 February 2013). General and Oral Pathology for the Dental Hygienist. Lippincott Williams & Wilkins. p. 663. ISBN 978-1-4511-3153-6.
- Guide to Yeast Genetics and Molecular Biology: Volume 194: Guide to Yeast Genetics and Molecular Biology. Gulf Professional Publishing. 14 May 2004. p. 751. ISBN 978-0-08-057513-1.
- "Green Power Purchasers Fortune 500 List". Archived from the original on 2008-05-11.
- "Newsweek, Greenest Big Companies in America – The 2009 List". Archived from the original on 2009-09-24.
- "Newsweek, Green Ranking 2009 - Becton Dickinson". Archived from the original on 2009-09-26.
- "Dow Jones Sustainability Indexes" (PDF). Archived from the original (PDF) on 2008-07-04.
- Pfitzer, M., Bockstette, V. and Stamp, M., Innovating for Shared Value, Harvard Business Review, September 2013, accessed 24 July 2022
- "OSHA finds dozen violations at Becton, Dickinson and Co. in Holdrege after two workers suffer finger amputations". OSHA. April 12, 2016. Retrieved April 18, 2016.
- "Becton Dickinson dystrybutor - Sprzęt medyczny BD Medical Systems". www.skamex.com.pl. Retrieved 2019-01-16.
- "Reuters: Becton Dickinson expands syringe recall in Poland". 2007-08-06.
- "Reuters: Becton Dickinson recalls intravenous devices". 2010-02-08.
- "Millions of BD IV giving sets recalled amid contamination concerns". NursingNotes. 2021-03-22. Retrieved 2021-05-27.
- "National Patient Safety Alert: Supply disruption of sterile infusion sets and connectors manufactured by Becton Dickinson (BD) (NatPSA/2021/001/MHRA)". GOV.UK. Retrieved 2021-05-27.
- Business data for Becton Dickinson:
This article is a direct transclusion of the Wikipedia article and therefore may not meet the same editing standards as LIMSwiki.